Poxel (FRA:7PO) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7PO Poxel SA FRA:7PO
43 GF Score
Price €0.20
GF Value €1.28
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:7PO
43GF Score
Poxel SA FRA:7PO
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (FRA:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 84.6% below its estimated GF Value™ of €1.28. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for FRA:7PO:

  • Short Ratio:
  • GF Value™: €1.28 vs. price of €0.20 (84.6% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Poxel Business Description

Other Exchanges 0RA2:UKPOXEL:France
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
43GF Score

Get the complete analysis for FRA:7PO

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.28
GF Value